NCT02716610View on ClinicalTrials.gov

Dose-Response and Variability of Inhaled Insulin in Type 2 Diabetes

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

October 31, 2013

Primary Completion Date

January 31, 2014

Study Completion Date

January 31, 2014

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

INH 69 U (low)

inhaled human insulin

DRUG

INH 69 U (high)

inhaled human insulin

DRUG

INH 139 U

inhaled human insulin

DRUG

INH 208 U

inhaled human insulin

DRUG

LIS 18 U

subcutaneous insulin lispro

Sponsors
All Listed Sponsors
lead

Dance Biopharm Inc.

INDUSTRY

NCT02716610 - Dose-Response and Variability of Inhaled Insulin in Type 2 Diabetes | Biotech Hunter | Biotech Hunter